Work

Phase II trial of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehydethiosemicarbazone plus gemcitabine in patients with advanced biliary tract cancer

Year: 2010

Type: article

Study design: Clinical Trial

Source: Cancer Chemotherapy and Pharmacology

DOI: 10.1007/s00280-010-1481-z

Authors: Allyson J. Ocean, Paul Christos, Joseph A. Sparano, Dan Matulich, Andreas Kaubish, Abby Siegel, Max Sung, Maureen M. Ward, Nancy Hamel, Igor Espinoza-Delgado, Yun Yen, Maureen E. Lane

Institutions: NewYork–Presbyterian Hospital, Cornell University, Weill Cornell Medicine, Albert Einstein College of Medicine, Montefiore Medical Center, Columbia University, Icahn School of Medicine at Mount Sinai, National Institutes of Health, National Cancer Institute, National Cancer Institute, City Of Hope National Medical Center, City of Hope

Language: English

Topic: Cholangiocarcinoma and Gallbladder Cancer Studies

Subfield: Surgery

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funders: National Institutes of Health, National Cancer Institute

Awards: Early Therapeutics Development with Phase II Emphasis, G3424222379, Methylation and Hepatocellular Carcinoma Outcomes

OpenAlex ID: W2026697163

FWCI: 0.93

Cites: 35

Cited by: 26

Related to: 10